Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day

INTRODUCTION: In hereditary tyrosinemia type 1 (HT1) patients, the dose of NTBC that leads to the absence of toxic metabolites such as succinylacetone (SA) is still unknown. Therefore, the aims of this study were to investigate the variation and concentrations of 2-(2-nitro-4-trifluormethyl-benzyl)-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kienstra, Nienke S., van Reemst, Hannah E., van Ginkel, Willem G., Daly, Anne, van Dam, Esther, MacDonald, Anita, Burgerhof, Johannes G. M., de Blaauw, Pim, McKiernan, Patrick J., Heiner-Fokkema, M. Rebecca, van Spronsen, Francjan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830494/
https://www.ncbi.nlm.nih.gov/pubmed/29170874
http://dx.doi.org/10.1007/s10545-017-0112-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830494/
https://www.ncbi.nlm.nih.gov/pubmed/29170874
http://dx.doi.org/10.1007/s10545-017-0112-9

Ejemplares similares